As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2 billion in 2023 to $73.2 billion in 2028, partly driven by soaring demand for outsourced trial providers.
However, clinical trial providers are facing challenges in completing trials efficiently, including long trial durations, increased competition for sites and participants, and complex protocols.
The US firm WCG uses a mixture of industry expertise, digital tools and data science to help its clients to overcome these challenges for companies running clinical trials. One is the platform ClinSphere, where users can store the diverse datasets and paperwork essential for running clinical trials, and harness artificial intelligence (AI) to speed up trial enrolment and other core components of running a clinical trial.
WCG is one of a crowd flocking to this year’s SCOPE Summit in Orlando, Florida, and we talked to chief technology officer, Paul Mancinelli, about the firm’s recent achievements and what it is looking forward to this year.
Can you tell me what milestones your company has hit since the previous SCOPE event in 2024?
2024 was a year of investment and growth for WCG. Last year at this time we launched our ClinTech platform: WCG ClinSphere, and we’ve continued to seamlessly integrate data, insights, and AI, to provide a robust platform that redefines how clinical trials are conducted end-to-end. We expanded our statistical consulting services, enhanced our study planning and review solutions, as well as our site enablement solutions, unveiled enhancements to our site network, and grew with the acquisition of Array in 2024.
What are the highlights of SCOPE for your team?
We’re looking forward to showcasing our latest solutions that integrate technology, data, and expertise to transform clinical trial processes, highlighted by the launch of WCG ClinSphere Total Enrollment, a powerful management tool designed to centralize and optimize participant recruitment and retention for sponsors and sites. We are also excited to have our thought leaders present sessions on timely and critical topics such as site feasibility, artificial intelligence, and recruitment and retention.
What do you expect to achieve from the event this year?
We aim to connect with sponsors, CROs, and sites to understand their challenges and demonstrate how WCG’s technology, including AI and automation, can drive more efficient and effective clinical trials, ultimately improving outcomes and fostering sustained growth for our clients.
How do you see this year panning out for your team in general?
WCG’s deep expertise and focus on investments in technology makes us well positioned as a strategic partner helping our clients overcome market challenges in 2025 and beyond. We will continue to focus on investments in tech and AI to enhance our collaborative efforts across the industry, from IRB to site enablement to clinical endpoints. By fostering stronger partnerships and integrating more robust, tech-driven solutions, we aim to streamline processes and improve outcomes for all stakeholders. Our goal is to become the global leader in clinical trial and site enablement, driving superior results and innovation in clinical research.
